Table 4.

Histopathology in the modified intention-to-treat population.

	RPD n = 29	OPD n = 33	p value
Malignant disease	16 (55.2%)	18 (54.5%)
Benign neoplastic lesion	9 (31.0%)	9 (27.3%)
Benign non-neoplastic lesion	4 (13.8%)	6 (18.2%)
Pancreatic cancer subtype according to the current classification of the WHO
Pancreatic ductal adenocarcinoma	12 (75.0%)	10 (55.6%)
Intraductal papillary-mucinous carcinoma	0 (0.0%)	3 (16.7%)
Ampullary cancer	1 (6.3%)	2 (11.1%)
Intrapancreatic cholangiocarcinoma	1 (6.3%)	2 (11.1%)
Neuroendocrine tumour	1 (6.3%)	0 (0.0%)
Other	1 (6.3%)	1 (6.7%)
Resection			0.154
R0 CRM−	7 (43.8%)	9 (50.0%)
R0 CRM+	6 (37.5%)	9 (50.0%)
R1	3 (18.8%)	0 (0.0%)

Values in parentheses are percentages unless indicated otherwise; CRM: Circumferential resection margin. No p values were calculated regarding histopathological results as these cannot be influenced by the trial intervention.